

RECEIVED  
JUL 09 2001  
TECH CENTER 1600/2900

CLEAN COPY OF AMENDMENTS

In the Specification

Please delete lines 16-20, Page 1 of the Specification.

Please enter the following as the first paragraph of the Specification.

Cross Reference to Related Application

AI  
The present application is a divisional application of U.S. Serial No. 09/545,139 filed April 7, 2000, <sup>now 6,469,045</sup> which is a divisional application of U.S. Serial No. 08/950,673 filed October 16, 1997, which issued on June 6, 2000 as U.S. Patent No. 6,071,948 and which is a continuation-in-part of U.S. Serial No. 08/025,046 filed March 1, 1993 now abandoned.

In the Claims

Please cancel Claims 1-22.

Please enter new claims 23- 57 as they appear below.

Sub AL  
23. (New) A method for inhibiting tumor formation or growth by inhibiting angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis-inhibiting amount of thalidomide.

24. (New) The method of Claim 23 wherein in the tumor formation or growth is in a mammal.

25. (New) The method of Claim 24 wherein the thalidomide is administered orally, sublingually, buccally, rectally, vaginally, transdermally, topically, basally, or parenterally.

26. (New) The method of Claim 23 wherein the thalidomide is administered in the form of a tablet or capsule.